Rezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business Update
Globe Newswire•05/11/2026•16:05 ET
0
Key Highlights
- ➤upLIFT enrollment complete; topline tumor HI results expected by mid-December 2026
- ➤FDA recommended filing a BLA for congenital HI after a pre-BLA meeting
- ➤sunRIZE missed its primary endpoint despite clinically relevant CGM improvements
- ➤Rezolute plans to submit an ersodetug BLA for one or both indications in 2027
- ➤Cash, equivalents and investments fell to $90.0 million from $107.8 million
- ➤First-quarter net loss widened to $18.5 million from $18.2 million year over year
REDWOOD CITY, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today reported financial results and provided a business update for the first quarter ended September 30, 2026.
Tumor HI * upLIFT, a Phase 3, single-arm, open label study in up to 16 hospitalized participants for the treatment of tumor HI, is ongoing. * Enrollment is complete and topline results are expected by mid-December 2026.
Get started
Create a free account to read the full story.